Hydrogen sulfide and/or nitrite in the treatment and prevention of atrial fibrillation

Patent metadata

Field	Value
Publication number	US-11116731-B2
Application number	US-201816486596-A
Country	US
Kind code	B2
Filing date	Feb 20, 2018
Priority date	Feb 20, 2017
Publication date	Sep 14, 2021
Grant date	Sep 14, 2021

Abstract

A method of treating Atrial Fibrillation or a pre-Atrial Fibrillation condition in a mammal, preferably a human, comprising administering a therapeutically effective amount of one of organic or inorganic sulfide, organic or inorganic nitrite, both organic or inorganic sulfide and organic or inorganic nitrite, or pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or a combination thereof.

First claim

We claim:

1. A method of treating atrial fibrillation or a pre-atrial fibrillation condition in a mammal comprising: administering a pharmaceutical composition containing therapeutically effective amount of both diallyl trisulfide (DATS), and an inorganic nitrite, or a pharmacologically acceptable salt thereof; and formulating a relative level of diallyl trisulfide and nitrite in the pharmaceutical composition based on if the mammal is a male or female.

2. The method of claim 1 wherein the mammal is a male.

3. The method of claim 1 wherein the inorganic nitrite is one of ammonium nitrite (NH 4 NO 2 ), barium nitrite (Ba(NO 2 ) 2 ), calcium nitrite (Ca(NO 2 ) 2 ), cesium nitrite (CsNO 2 ), cobalt(II)nitrite (Co(NO 2 ) 2 ), cobalt(III)potassium nitrite (CoK 3 (NO 2 ) 6 ), lithium nitrite (LiNO 2 ), magnesium nitrite (MgNO 2 ), potassium nitrite (KNO 2 ), rubidium nitrite (RbNO 2 ), silver(I)nitrite (AgNO 2 ), strontium nitrite (Sr(NO 2 ) 2 ), and zinc nitrite (Zn(NO 2 ) 2 ), and wherein the inorganic nitrite is in one of a anhydrous and hydrated form.

4. The method of claim 1 wherein the inorganic nitrite is sodium nitrite.

5. The method of claim 1 wherein the mammal is a female.

6. The method of claim 1 wherein the mammal is a human.

7. The method of claim 1 wherein the pharmaceutical composition has a higher level of diallyl trisulfide to nitrite if the mammal is a male and has a lower level of sulfide to nitrite if the mammal is a female.

8. A pharmaceutical composition for treating atrial fibrillation or a pre-atrial fibrillation condition comprising; a therapeutically effective dose of diallyl trisulfide, and a therapeutically effective dose of inorganic nitrite, or a pharmacologically acceptable salt thereof.

9. The pharmaceutical composition of claim 8 wherein the inorganic nitrite is one of ammonium nitrite (NH 4 NO 2 ), barium nitrite (Ba(NO 2 ) 2 ), calcium nitrite (Ca(NO 2 ) 2 ), cesium nitrite (CsNO 2 ), cobalt(II)nitrite (Co(NO 2 ) 2 ), cobalt(III)potassium nitrite (CoK 3 (NO 2 ) 6 ), lithium nitrite (LiNO 2 ), magnesium nitrite (MgNO 2 ), potassium nitrite (KNO 2 ), rubidium nitrite (RbNO 2 ), silver(I)nitrite (AgNO 2 ), strontium nitrite (Sr(NO 2 ) 2 ), and zinc nitrite (Zn(NO 2 ) 2 ), and wherein the inorganic nitrite is in one of a anhydrous and hydrated form.

10. The pharmaceutical composition of claim 8 wherein the inorganic nitrite is sodium nitrite.

Assignees

• Univ Louisiana State
• Brd Of Sup Of Lsu And A &M College

Inventors

• Kevil Christopher G
• Dominic Paari

Classifications

• C01B21/50 Primary

  Nitrous acid; Salts thereof · CPC title

• C01B17/16

  Hydrogen sulfides · CPC title

• A61P9/06

  Antiarrhythmics · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K36/8962

  Allium, e.g. garden onion, leek, garlic or chives · CPC title